Automated Multiplex Immunofluorescennce

Thursday, September 19, 2019, 12:00 – 1:00PM Eastern (9:00 – 10AM Pacific)

Cancer research continues to push the boundaries with new advancements in tissue analysis and biomarker detection. Now, more than ever, there is significant emphasis on understanding the underlying interaction between the immune system and the tumor microenvironment and its role in disease progression. Multiplexing immunofluorescence (mIF) has greatly increased our understanding of solid tumor biology and immunology, including tumor-infiltrating lymphocytes and cancer-induced architectural alterations, and aided in novel immunology discoveries. In this webinar, we will discuss how Akoya Biosciences Phenoptics assays support quantitative mIF to overcome the limitations imposed by conventional IHC methodologies. We will also discuss how our Opal assay kits and reagents can be integrated with the Leica BOND RX to automate your staining workflow to support consistent results for high-throughput studies.

  • Understand the limitations of conventional IHC, and the benefits of transitioning to multiplex immunofluorescence
  • Learn how to design, optimize and analyze your multiplex assay panel
  • Understand how the BOND RX enables innovations like the Opal assay

Bethany Remeniuk, PhD
Global Applications Scientist
Akoya Biosciences

Traci DeGeer, BS, HT (ASCP) HTL, QIHC
Global Product & Innovation Manager
Leica Biosystems